Analysis of symptoms of patients with headaches and their response to treatment with ergot derivatives.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004874:Ergonovine / Q000008:administration & dosage / Q000627:therapeutic use*; D004878:Ergotamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000145:classification / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008784:Methysergide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008881:Migraine Disorders / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011346:Prochlorperazine / Q000627:therapeutic use; D013997:Time Factors; D014887:Weather
D004878:Ergotamine; D001241:Aspirin; D004874:Ergonovine; D008784:Methysergide; D011346:Prochlorperazine